Kymera Therapeutics (KYMR) Competitors

Qiagen (NYSE:QGEN) and Kymera Therapeutics (NASDAQ:KYMR) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, community ranking, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings.

Is QGEN or KYMR more profitable?

Qiagen has a net margin of 4.23% compared to Kymera Therapeutics' net margin of -191.26%. Qiagen's return on equity of 13.92% beat Kymera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	4.23%	13.92%	8.40%
Kymera Therapeutics	-191.26%	-24.96%	-20.27%

Which has better valuation and earnings, QGEN or KYMR?

Qiagen has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$1.98B	4.45	$83.59M	$0.36	110.25
Kymera Therapeutics	$47.07M	43.90	-$146.96M	-$2.97	-10.71

Do insiders and institutionals hold more shares of QGEN or KYMR?

70.0% of Qiagen shares are held by institutional investors. 9.0% of Qiagen shares are held by company insiders. Comparatively, 15.8% of Kymera Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Does the media refer more to QGEN or KYMR?

In the previous week, Qiagen and Qiagen both had 4 articles in the media. Kymera Therapeutics' average media sentiment score of 1.03 beat Qiagen's score of 0.96 indicating that Kymera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qiagen	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kymera Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community prefer QGEN or KYMR?

Qiagen received 192 more outperform votes than Kymera Therapeutics when rated by MarketBeat users. Likewise, 60.29% of users gave Qiagen an outperform vote while only 54.29% of users gave Kymera Therapeutics an outperform vote.

Company	Underperform	Outperform
Qiagen	Outperform Votes 249 60.29%	Underperform Votes 164 39.71%
Kymera Therapeutics	Outperform Votes 57 54.29%	Underperform Votes 48 45.71%

Do analysts rate QGEN or KYMR?

Qiagen currently has a consensus price target of $47.71, indicating a potential upside of 20.20%. Kymera Therapeutics has a consensus price target of $56.36, indicating a potential upside of 77.11%. Given Kymera Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Kymera Therapeutics is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	0 Sell rating(s)	7 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.30
Kymera Therapeutics	0 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.87

Which has more volatility & risk, QGEN or KYMR?

Qiagen has a beta of 0.44, indicating that its stock price is 56% less volatile than the S&P 500. Comparatively, Kymera Therapeutics has a beta of 2.22, indicating that its stock price is 122% more volatile than the S&P 500.

Summary

Qiagen beats Kymera Therapeutics on 10 of the 18 factors compared between the two stocks.